diabetestalk.net

The UK Prospective Diabetes Study (UKPDS): Clinical And Therapeutic Implications For Type 2 Diabetes

The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes

The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes


The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes
1Jenny ONeill Diabetes Centre, Derbyshire Royal Infirmary, Derby, UK
2Division of Vascular Medicine, School of Medical and Surgical Sciences, University of Nottingham, UK
1Jenny ONeill Diabetes Centre, Derbyshire Royal Infirmary, Derby, UK
2Division of Vascular Medicine, School of Medical and Surgical Sciences, University of Nottingham, UK
Correspondence: Dr I. Peacock, Derbyshire Royal Infirmary, London Road, Derby, DE1 2QY, UK.
Note added in proof We wish to pay tribute to Robert Turner whose recent untimely death is such a tragedy.
Received 1999 Mar 15; Accepted 1999 Aug 24.
Keywords: antihypertensives, diabetic complications, glycaemic control, oral hypoglycaemic agents, type 2 diabetes, UKPDS
This article has been cited by other articles in PMC.
Diabetes was first recognized 3500 years ago by the Ancient Egyptians. One of the first clinical descriptions was by Aretaeus, who practised in Cappadocia around 120 AD. He wrote that the condition was fortunately rare, but short will be the life of the man in whom the disease is fully developed [ 1 ].
In modern society, the first statement is far from true. The incidence of diabetes has doubled every 20 years since 1945 [ 2 ]. In 1994 the world wide prevalence of type 2 (non-insulin dependent) diabetes was 99 million (1.8% of the population); by 2010 it is estimated that this figure will rise to 215 million (3.8%) [ 3 ].
The second statement is as true today as it was almost 2000 years ago. In the West, 44% of pat Continue reading

Rate this article
Total 1 ratings
Diabetes Patients Seeing Better Outcomes Through Technology

Diabetes Patients Seeing Better Outcomes Through Technology


Tuesday, June 06, 2017 |by Paul Wynn, special to AAMCNews
Diabetes Patients Seeing Better Outcomes Through Technology
When David Klonoff, MD, started practicing endocrinology more than 35 years ago, urine tests were the standard for diabetes screenings. We had to mix chemicals with the urine to get a resultand it wasnt very accurate, said Klonoff, a clinical professor at the University of California, San Francisco (UCSF), School of Medicine and founding editor in chief of the Journal of Diabetes Science and Technology.
Fast-forward to 2017. Continuous glucose monitoring systems can measure blood glucose every five minutes or up to 300 times a day. Sensors built into advanced systems enable patients to sidestep the need to prick their fingers to collect blood. Klonoff, a specialist in diabetes technology, coauthored a study on the first-generation system of an artificial pancreas that can automatically send information to an insulin pump to adjust unhealthy blood glucose levels. He was lead investigator for the first in-home pivotal trial of a closed-loop product for managing type 1 diabetes, and he participated in developing the first dedicated diabetes telemedicine system cleared by the Food and Drug Administration. The system increases access to expertise for people in remote areas or without transportation.
"The new technologies for the testing and treatment of diabetes in the past few decades have been astounding and are making a major difference in improving the outcomes.
Academic medical centersUCSF and othersare uniquely positioned to bring together technology Continue reading

Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement

Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement


, Volume 60, Issue11 , pp 21682173 | Cite as
Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement
The majority of infants with neonatal diabetes mellitus present with severe ketoacidosis at a median of 6weeks. The treatment is very challenging and can result in severe neurological sequelae or death. The genetic defects that cause neonatal diabetes are present from birth. We aimed to assess if neonatal diabetes could be diagnosed earlier by measuring glucose in a dried blood spot collected on day 5 of life.
In this retrospective casecontrol study we retrieved blood spot cards from 11 infants with genetically confirmed neonatal diabetes (median age of diagnosis 6 [range 2112] days). For each case we also obtained one (n=5) or two (n=6) control blood spot cards collected on the same day. Glucose was measured on case and control blood spot cards. We established a normal range for random glucose at day 5 of life in 687 non-diabetic neonates.
All 11 neonates with diabetes had hyperglycaemia present on day 5 of life, with blood glucose levels ranging from 10.2mmol/l to >30mmol/l (normal range 3.26.0mmol/l). In six of these neonates the diagnosis of diabetes was made after screening at day 5, with the latest diagnosis made at 16weeks.
Neonatal diabetes can be detected on day 5 of life, preceding conventional diagnosis in most cases. Earlier diagnosis by systematic screening could lead to prompt genetic diagnosis and targeted treatment, thereby avoiding the most severe sequelae of hyperglycaemia in neonates.
Blood spotsGlucoseNeonatal d Continue reading

Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus

Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus


#Springer Science+Business Media New York 2016
Abstract Medical nutrition therapy (MNT) plays an impor-
tant role in the management of gestational diabetes mellitus
(GDM), and accordingly, it has a significant impact on women
and newborns. The primary objective of MNT is to ensure
adequate pregnancy weight gain and fetus growth while main-
taining euglycemia and avoiding ketones. However, the opti-
mal diet (energy content, macronutrient distribution, its qual-
ity and amount, among others) remains an outstanding ques-
tion. Overall, the nutritional requirements of GDM are similar
for all pregnancies, but special attention is paid to carbohy-
drates. Despite the classical intervention of restricting carbo-
hydrates, the latest evidence, although limited, seems to favor
a low-glycemic index diet. There is general agreement in the
literature about caloric restrictions in the case of being over-
weight or obese. Randomized controlled trials are necessary to
investigate the optimal MNT for GDM; this knowledge could
Keywords Carbohydrates .Diet .Gestational diabetes .
Gestational diabetes mellitus .Medical nutrition therapy .
Gestational diabetes mellitus (GDM) is a frequent metabolic
condition associated with pregnancy that leads to substantial
maternal and perinatal complications. Medical nutrition ther-
apy (MNT) remains the main strategy for the treatment of
gestational diabetes [1]. However, there is still insufficient
evidence as to which is the optimal type of dietary advice.
This paper revises the available evidence from studies on this
matter Continue reading

Today is World Diabetes Day

Today is World Diabetes Day


The journey to positive living with diabetes.
World Diabetes Day is celebrated annually on November 14.
It was created in 1991 in response to growing concerns about the escalating health threat posed by diabetes.
Hearing the diagnosis for the first time that you have diabetes can be overwhelming and may leave you with mixed emotions its stressful, it requires an entirely new approach to aspects such as lifestyle and diet, and its tough to manage.
But its perfectly possible to lead a healthy, fulfilling and active life with the right healthcare and family support, medication and personal attitude, explained Dr Ntsiki Molefe-Osman, Diabetes Medical Advisor at Lilly South Africa.
Diabetes comes in two types Type 1 and Type 2.
If you have Type 1 diabetes, your body is unable to produce sufficient insulin of its own in order to maintain healthy blood sugar levels in the body.
It usually begins in childhood or adolescence and is caused by a faulty autoimmune response that causes the body to destroy the pancreatic cells that produce insulin, which in turn leads to an insulin deficiency.
People with type 1 diabetes must take insulin as it is vital to staying healthy and achieving the most consistently normal sugar levels, and quality of life.
Theres no cure for type 1 diabetes although researchers are working on preventing the disease as well as the further destructive progression of the disease in people who are newly diagnosed.
Type 2 diabetes is far more common and according to the International Diabetes Federation (IDF), there were 2.28 million diagnosed cases of Continue reading

No more pages to load

Popular Articles

  • Clinical Trials and the Type 1 Diabetes Cure
    Clinical Trials and the Type 1 Diabetes Cure

    WRITTEN BY: Stephen Gitelman, MD I am often asked the question, “Where is the cure for Type 1 diabetes (T1D)?” For those with long-standing diabetes, we are very close to replicating insulin producing beta cell functionality or the actual replacement of those cells — either with closed loop systems with continuous glucose sensor driving an insulin pump, or use of replacement beta cells deriv ...

  • 4 Promising New and Upcoming Clinical Trials for Type 1 Diabetes
    4 Promising New and Upcoming Clinical Trials for Type 1 Diabetes

    Type 1 Diabetes is a disease where your own immune system mistakenly attack your “pancreatic islets”- small clusters of cells in the pancreas that contain insulin-producing “beta” cells. There is currently no cure for Type 1 Diabetes, although it can be managed. Type 1 diabetics must carefully time when and what they eat, monitor their blood glucose by pricking their fingers, and routinely ...

  • Diet Soda Intake and Risk of Incident Metabolic Syndrome and Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA)*
    Diet Soda Intake and Risk of Incident Metabolic Syndrome and Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA)*

    Go to: We determined associations between diet soda consumption and risk of incident metabolic syndrome, its components, and type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis. Diet soda consumption was assessed by food frequency questionnaire at baseline (2000–2002). Incident type 2 diabetes was identified at three follow-up examinations (2002–2003, 2004–2005, and 2005–2007) as ...

  • Immunotherapy treatment shown safe in type 1 diabetes clinical trial
    Immunotherapy treatment shown safe in type 1 diabetes clinical trial

    A small clinical trial showed an immune system therapy was safe for people with type 1 diabetes, British researchers report. The immunotherapy also showed signs of helping to keep insulin production steady in people newly diagnosed with the disease, the study authors said. However, because this was a placebo-controlled safety trial, there weren't enough people included to know for sure how well th ...

  • A Clinical Trial Just ‘Reversed’ Type 2 Diabetes in 40% of Participants
    A Clinical Trial Just ‘Reversed’ Type 2 Diabetes in 40% of Participants

    Researchers conducted a pilot study in which patients with type 2 diabetes underwent a medical intervention that included glucose-controlling drugs and a strict diet and exercise regiment. Four months after the intervention, the study revealed that 40 percent of the 83 subjects were able to effectively stop taking their medications, staying in partial or even complete remission. Reversing Type 2 D ...

  • Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial
    Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

    Abu Dhabi, Uae (ots/PRNewswire) - Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people with type 2 diabetes whose blood sugar was not controlled on insulin glargine U100 with metformin, and who completed quality-of-life questionnaires as part of the DUAL VII cl ...

  • New clinical trial could offer a functional cure for people with type 1 diabetes
    New clinical trial could offer a functional cure for people with type 1 diabetes

    New clinical trial could offer a functional cure for people with type 1 diabetes New clinical trial could offer a functional cure for people with type 1 diabetes The ViaCyte trial is being run at three sites in North America, including University of Minnesota Health. Greg Romero (right) has to live with his type 1 diabetes all day, every day. But a new clinical trial offered through Universit ...

  • Care of the Athlete With Type 1 Diabetes Mellitus: A Clinical Review
    Care of the Athlete With Type 1 Diabetes Mellitus: A Clinical Review

    Care of the Athlete With Type 1 Diabetes Mellitus: A Clinical Review 1Department of Medicine, University of Mississippi Medical Center, Mississippi, United States 2Division of Endocrinology, University of Mississippi Medical Center, Mississippi, United States 3Department of Medicine, G.V. Montgomery VA Medical Center, Mississippi, Jackson, United States 1Department of Medicine, University of ...

  • Metformin: clinical use in type 2 diabetes
    Metformin: clinical use in type 2 diabetes

    , Volume 60, Issue9 , pp 15861593 | Cite as Metformin: clinical use in type 2 diabetes Metformin is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there still remains controversy regarding the drugs precise mechanism of action, which is thought to involve a reduction in he ...

Related Articles